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Background
Bendamustine may be a potential treatment option for patients with myeloma, but little 
is known about the utility of bendamustine as a salvage treatment, especially in Asian 
patients.
Methods
We performed a multicenter retrospective study of patients with relapsed or refractory 
myeloma who received bendamustine and prednisone. 
Results
The records of 65 heavily pre-treated patients, who had undergone bortezomib and lenali-
domide treatment (median number of previous treatments: 5), were analyzed. The me-
dian time from diagnosis to bendamustine treatment was 3.8 years, and the median pa-
tient age was 63 years (range, 38‒77 yr). The responses to the last treatment before bend-
amustine were refractory disease (N=52, 80%) or disease progression from partial re-
sponse (N=13, 20%). Twenty-three patients responded to the treatment, with an overall 
response rate of 35% (23/65), and the median number of bendamustine treatment cycles 
was two (range, 1‒5 cycles). The median overall survival after bendamustine treatment 
was 5.5 months and the overall survival rate in responders to bendamustine was sig-
nificantly better than that in non-responders (P=0.036). 
Conclusion
Bendamustine may be a potential salvage treatment to extend survival in a select group 
of heavily pre-treated patients with relapsed or refractory myeloma.
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INTRODUCTION
Multiple myeloma (MM) is a plasma cell neoplasm charac-
terized by the accumulation of clonal bone marrow plasma 
cells that produce abnormal monoclonal immunoglobulin 
which can be detected in the blood and/or urine; MM ac-
counts for approximately 10% of all hematologic malig-
nancies [1]. Survival outcomes for patients with MM have 
substantially improved over the last two decades due to treat-
ment with high-dose chemotherapy followed by autologous 
stem cell transplantation (ASCT), as well as novel agents 
such as bortezomib and immunomodulatory drugs (IMIDs) 
that have become available in both the upfront and relapse 
settings [2-4]. Nevertheless, almost all patients ultimately 
relapse and become refractory to salvage treatments with 
few options for management. Many new drugs such as carfil-
zomib and pomalidomide have been approved for the treat-
ment of relapsed or refractory MM patients previously treated 
with bortezomib and lenalidomide. However, their use re-
mains limited due to their high cost in many countries, 
including Korea. Accordingly, treatment options for patients 
who relapse after bortezomib and IMIDs have been limited 
in Korea, especially for elderly patients who are not eligible 
for stem cell transplantation [5-7]. 
Since its approval for MM patients in 2011, bendamustine 
has emerged as a treatment option for patients with relapsed 
or refractory MM in Korea. A bi-functional alkylating agent 
with structural similarities to both alkylating agents and 
purine analogues, bendamustine induces anti-tumor effects 
by causing intra- and inter-strand cross-links between DNA 
bases that are more extensive and durable than those caused 
by other alkylating agents [8, 9]. Thus, bendamustine shows 
incomplete cross-resistance with cyclophosphamide and 
melphalan [10-12]. Since its development in East Germany, 
bendamustine, alone or in combination with steroids or other 
novel agents, has been used in the treatment of patients 
with MM in the clinical trial setting. However, there is 
limited data available regarding the efficacy of bendamustine 
in an unselected, real-life population with relapsed or re-
fractory MM. Thus, we analyzed treatment outcomes in 
heavily pre-treated patients who received bendamustine dur-
ing clinical practice for relapsed or refractory myeloma. 
MATERIALS AND METHODS
Study design
The Korean Multiple Myeloma Working Party proposed 
a nationwide retrospective study to examine bendamustine 
as a salvage treatment for heavily pre-treated patients with 
relapsed or refractory MM (KMM125 study). The primary 
endpoints were overall survival (OS) and progression-free 
survival (PFS) after bendamustine treatment. The secondary 
endpoints were overall response rate (ORR), which was cate-
gorized as either complete response (CR), very good partial 
response (VGPR), or partial response (PR); and treat-
ment-related hematologic and non-hematologic toxicities. 
Response was assessed using the International Myeloma 
Working Group uniform response criteria [13-15]. Patients 
who satisfied all of the following criteria were included: 
1) pathologically diagnosed with MM, 2) received at least 
two kinds of treatment prior to bendamustine-containing 
treatment between 2011 and 2013, and 3) underwent at 
least one cycle of bendamustine. Medical record reviews 
and data collections were performed by investigators from 
participating institutes. Response rates and toxicities were 
analyzed in April 2014, and the final analysis, including 
survival outcomes, was performed after the final survival 
status update in December 2015. Given that the study was 
a retrospective analysis with the purpose of a nationwide 
survey, the sample size calculation was based on the total 
number of patients who satisfied the inclusion criteria during 
the study period. All aspects of the study were reviewed 
and approved by the Institutional Review Board (IRB) of 
Samsung Medical Center (No. 2012-07-042), and by each 
IRB of the participating institutions. The requirement for 
individual informed consent was waived due to the minimal 
risk that the study posed to participants. 
Treatment and evaluation
Treatment consisting of bendamustine and the steroid pre-
dnisone was administered every 4 weeks (28-day cycles). 
Bendamustine was administered intravenously at a dose of 
120 mg/m2 per day on days 1 and 2, in combination with 
prednisone at a dose of 60 mg/m2 per day, or a fixed dose 
of 100 mg per day, on days 1–4. The response evaluation 
was repeated every cycle with serum and 24-hour urine 
electrophoresis and immunofixation, and a serum-free light 
chain assay. The ORR was based on the best response during 
treatment; therefore, if a patient showed disease progression 
after responding to treatment before the end of treatment, 
they were counted as a responder. Response was assessed 
according to the International Uniform Response Criteria 
for Multiple Myeloma [13, 14]. Toxicities were graded ac-
cording to the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events, version 3.0, and 
the maximum toxicity grade per patient was recorded. 
Statistical analysis
Fisher’s exact test was used for categorical data and survival 
outcomes were calculated using Kaplan-Meier curves and 
compared using the log-rank test. OS after bendamustine 
treatment was calculated from the start date of bendamustine 
treatment to the date of any cause-related death or the last 
follow-up date. PFS after bendamustine treatment was de-
scribed as survival duration between the start date of bend-
amustine treatment to the date of relapse or progression 
or any kind of death. P-value＜0.05 was considered to be 
significant, and the analysis was performed using the 
Statistical Package for the Social Sciences (SPSS v.18.0). 
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Table 1. Clinical and laboratory characteristics of the patients.
Characteristics at diagnosis and prior to bendamustine Characteristics at the time of bendamustine treatment
N (%) N (%)
Age (yr) ＞65 14 (22) Age (yr) ＞65 24 (37)
≤65 51 (78) ≤65 41 (63)
Gender Male 39 (60) ISS stage I 7 (11)
Female 26 (40) II 20 (31)
Immunophenotype IgG/kappa 16 (24) III 35 (54)
IgG/lambda 11 (17) DS stage I 3 (5)
IgA/kappa 14 (22) II 8 (12)
IgA/lambda 5 (8) III 54 (83)
IgD/lambda 1 (2) Serum LDH Elevated 35 (54)
Kappa 6 (9) Normal 25 (38)
Lambda 8 (12) Unavailable 5 (8) 
Non-secretory 4 (6) ECOG PS 0/1 28 (43)
Induction treatment VAD 25 ≥2 37 (57)
TD/TCD/MPT 7/7/1 Hemoglobin ≥10 g/dL 26 (40)
BD/BMP/BAD 3/5/1 ＜10 g/dL 39 (60)
CD/MP 10/4 White blood cell ≥2,000 mm2 60 (92)
LD 2 ＜2,000 mm2 5 (8)
ASCT after induction Done 36 (55) Lymphocyte count ≥1,000 mm2 39 (60)
Not done 29 (45) ＜1,000 mm2 26 (40)
Second SCT ASCT 10 Platelet ≥75,000 mm2 34 (52)
Allogeneic SCT 1 ＜75,000 mm2 31 (48)
Previous treatment Bortezomib 65 (100) Creatinine clearance ＜30 mL/min 16 (25)
Lenalidomide 42 (65) 30–50 mL/min 8 (12)
Thalidomide 55 (85) ≥50 mL/min 41 (63)
Melphalan 45 (69) Response to last treatment Resistant 52 (80)
Cyclophosphamide 60 (92) Relapsed 13 (20)
Doxorubicin 31 (48)
N of previous lines 
of treatment
＜5 24 (37)
≥5 41 (63)
Abbreviations: ASCT, autologous stem cell transplantation; BAD, bortezomib, doxorubicin, dexamethasone; BD, bortezomib, dexamethasone; 
BMP, bortezomib, melphalan, prednisolone; CD, cyclophosphamide, dexamethasone; DS, Durie-Salmon; ECOG, Eastern Cooperative 
Oncology Group; ISS, International Staging System; LD, lenalidomide, dexamethasone; LDH, lactate dehydrogenase; MP, melphalan, 
prednisolone; MPT, melphalan, prednisolone, thalidomide; PS, performance status; TD, thalidomide, dexamethasone; TCD, thalidomide, 
cyclophosphamide, dexamethasone; SCT, stem cell transplantation; VAD, vincristine, doxorubicin, dexamethasone.
RESULTS
Patient characteristics 
We collected data for 65 patients who received bendamus-
tine treatment between November 2011 and September 2013 
at 10 hematological institutions in Korea. The median age 
at initial diagnosis of MM was 57 years (range, 37–75 yr), 
and the male-to-female ratio was 1.5：1. All patients had 
≥10% plasma cells in the bone marrow at diagnosis, and 
23 patients had ＞50% of plasma cells. The most common 
immunophenotype was IgG/kappa (Table 1). Cytogenetic 
information at diagnosis, based on conventional cytogenetics 
and fluorescence in-situ hybridization, was available only 
for 41 patients. Of these, 26 patients showed abnormal cyto-
genetics such as deletion 13q (N=5), t(11:14) (N=4), t(4:14) 
(N=4), t(14:16) (N=2), and deletion 17p (N=2). Thirty-six 
patients who were diagnosed with MM between November 
2001 and April 2013 underwent ASCT after induction treat-
ment, such as VAD (vincristine, doxorubicin, and dex-
amethasone), and thalidomide-containing treatment (Table 
1). The median number of previous treatments was five 
(range, 2–12), and the median time to bendamustine treat-
ment was 3.8 years (range, 0.2–10.4 yr). As a result, the 
median age at the time of the first bendamustine treatment 
cycle was 63 years (range, 38–77 yr), and a substantial number 
of patients had advanced disease with impairment of renal 
and bone marrow function (Table 1). The responses to the 
last treatment before bendamustine treatment were re-
fractory disease (N=52, 80%) or disease progression from 
partial response (N=13, 20%). 
Response and toxicity
The median dosage of bendamustine was 120 mg/m2, al-
though, in five patients, the dose of bendamustine was re-
duced to 100 mg/m2 in subsequent cycles of treatment based 
on the physician’s decision. Out of 65 patients, the response 
to treatment was evaluated in 62 patients; the response of 
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Table 2. Toxicity profiles.
All grades, N (%) Grade 3 and 4, N (%)
Neutropenia 54 (83) 39 (65)
Anemia 27 (42) 14 (22)
Thrombocytopenia 43 (66) 30 (46)
Sensory neuropathy 6 (9) 0 (0)
Nausea/vomiting 1 (2) 0 (0)
Diarrhea 1 (2) 0 (0)
Anorexia 2 (3) 0 (0)
Fatigue 10 (15) 0 (0)
Pneumonia 9 (14) 5 (8)
Sepsis 6 (9) 5 (8)
Fig. 1. (A, B) Median overall survival (OS) and progression-free survival (PFS) after bendamustine treatment was 5.5 months (95% confidence 
interval [CI], 3.5–7.5 mo) and 3.1 months (95% CI, 2.4–3.8 mo), respectively. 
three patients who died due to sepsis after the first bendamus-
tine treatment cycle was not evaluated. Based on the best 
response achieved, 23 patients responded to the treatment; 
this included one case of CR, five cases of VGPR and 17 
cases of PR, for an ORR of 35% (23/65). However, 18 patients 
showed early disease progression during treatment. The me-
dian number of bendamustine treatment cycles was two 
(range, 1–5 cycles). Reasons for discontinuation included 
lack of response (stable disease or progressive disease, N=39), 
infectious complications (N=10), and other reasons (N=16), 
such as non-infectious complications and early discontinua-
tion due the high cost of treatment for uninsured patients. 
Based on the maximum toxicity in each patient during treat-
ment, hematologic toxicities were the most commonly ob-
served toxicities (Table 2). Grade 3/4 neutropenia was found 
in 65% of patients, although most non-hematologic toxicities 
were less than grade 3. Frequent neutropenia and frailty 
in the majority of patients due to significant previous treat-
ments and disease progression meant that infectious compli-
cations were not uncommon, and 10 patients died due to 
infectious complications of pneumonia (N=5) and sepsis 
(N=5).
Survival outcome
At the final update, 59 patients had died and only six 
patients were still alive. Thus, the median OS and PFS after 
bendamustine treatment was 5.5 months (95% confidence 
interval [CI]: 3.5–7.5 mo) and 3.1 months (95% CI: 2.4–3.8 
mo), respectively (Fig. 1). Even though the median OS was 
short, 14 patients (22%) lived longer than 12 months after 
they started bendamustine treatment (range, 12–45 mo). The 
OS in patients who responded to bendamustine was sig-
nificantly better than that of patients who did not (P=0.036, 
Fig. 2). Performance status was significantly associated with 
OS, and a trend towards improved OS was also observed 
in patients≤60 years old (Fig. 2). However, the median 
number of treatment lines prior to bendamustine treatment 
was not associated with OS (Fig. 2). 
DISCUSSION
In this study, bendamustine combined with prednisone 
resulted in an ORR of 35% (23/65), including one case of 
CR and five cases of VGPR. However, the majority of patients 
showed early progression or treatment-related events, yield-
ing a median PFS of 3.1 months and a median OS of 5.5 
months after bendamustine treatment (Fig. 1). The treatment 
outcome in our study appeared to be less significant than 
outcomes achieved in recent clinical trials that combined 
bendamustine with novel agents such as lenalidomide and 
bortezomib [16, 17]. However, the outcome of our study 
population may not be comparable to those clinical trials 
for several reasons. First, our study population reflected un-
selected, heavily pre-treated real-life patients that were en-
countered in our clinical practice. As a result, more than 
half of the patients had a poor performance status (≥Eastern 
Cooperative Oncology Group [ECOG] grade 2), and a sub-
stantial number of patients had uni- or bi-lineage cytopenia 
as well as impaired renal function at the time of bendamustine 
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Fig. 2. (A) The OS of patients who responded to bendamustine was significantly better than that of patients who did not. (B) Performance status 
at the time of bendamustine treatment was significantly associated with OS. (C) Patients ≤60 years old at the time of bendamustine treatment 
showed a trend towards better OS. (D) The median number of lines prior to bendamustine treatment was not associated with OS.
treatment (Table 1). Second, more than 60% of patients un-
derwent at least five lines of treatment, including bortezomib 
and IMIDs, prior to bendamustine treatment. Furthermore, 
80% of patients were resistant to their last treatment; there-
fore, the likelihood of treatment resistance may have been 
higher in our patients than those enrolled in clinical trials. 
Third, bendamustine was used only in combination with 
prednisone because the combination with other novel agents 
was not allowed in clinical practice in Korea. The limited 
use of bendamustine may also have affected outcome, since 
a lack of national insurance coverage for bendamustine pre-
vented continuous treatment, even in responders. For these 
reasons, the outcome of bendamustine treatment in this study 
should be interpreted cautiously. 
When we compared our results with previously reported 
series that evaluated outcome with bendamustine in un-
selected, heavily pre-treated patients with relapsed or re-
fractory MM, the response rate and survival outcomes of 
our patients were comparable (Table 3). A previous study 
based on the French compassionate-use program reported 
overall response rates and survival outcomes that were similar 
to those in our study [12]. Patient characteristics at the 
time of bendamustine treatment were also similar in terms 
of previous treatments and the percentage of patients who 
were refractory to their last treatment (Table 3). Recently, 
an Italian study also reported an ORR of only 29% and 
a median OS of 7.3 months following various bendamus-
tine-containing salvage treatments in an unselected patient 
population that more accurately reflected patients encoun-
tered in clinical practice [18]. Although another retrospective 
study reported a better outcome with an ORR of 59% and 
a median OS of 17 months, the patient characteristics in 
that study were different to those in other studies, including 
ours, in terms of previous treatments and the percentage 
of patients refractory to their last treatment [19]. 
In our study, the incidence of grade 3/4 neutropenia (65%) 
was higher than that of previous studies (Table 3). As a 
result, 10 patients died due to infectious complications asso-
ciated with pneumonia (N=5) and sepsis (N=5). This high 
incidence of infectious complications may be associated with 
the frequent occurrence of neutropenia and the poor health 
of the patients due to underlying diseases and comorbidities. 
Blood Res 2016;51:193-9. bloodresearch.or.kr
198 Seok Jin Kim, et al. 
Table 3. Comparisons between multicenter studies of bendamustine treatment for relapsed or refractory myeloma.
Study [Reference] Italian study [18] German study [19] French study  [12] Korean study
N of patients 78 58 110 65
Median age, yr (range) 65 (38–84) 69 (43–85) 63 (34–83) 63 (38–77)
N of institutions 18 2 13 10
Median no. of previous lines of treatment (range) 4 (1–10) 4 (1–10) 4 (1–9) 5 (2–12)
Previous treatment with bortezomib, N (%) 74 (95%) 30 (52%) 110 (100%) 65 (100%)
Previous treatment with lenalidomide, N (%) 67 (85%)a) 16 (28%) 93 (85%) 42 (65%)
Response to the last therapy
No (resistant) 57 (73%) 20 (34%) 82 (75%) 52 (80%)
Yes (relapsed)  21 (27%) 38 (66%) 8 (7%) 13 (20%)
Missing data 20 (18%)
Previous transplant
Autologous SCT 47 (60%) 20 (34%) 66 (60%) 36 (55%)
Allogeneic SCT 3 (4%) Not reported Not reported 1 (2%)
Median no. of bendamustine cycles, N (range) 3 (1–9) 3 (1–8) 4 (1–13) 2 (1–5)
Dose of bendamustine (mg/m2) 60–150 60–300 60-150 120
Overall response rate (≥PR) 21/73 (29%)b)
 Bendamustine±steroid 4/39 (10%) 34/58 (59%) 33/110 (30%) 23/65 (35%)
 Bendamustine+bortezomib 7/18 (39%)  
 Bendamustine+lenalidomide 10/16 (62%)  
Hematological toxicity (≥G3) 44 (56%) 41 (71%)c) Not reported 39 (65%)d)
Non-hematological toxicity (≥G3) 12 (15%) 0 (0%) Not reported
Median OS after bendamustine (mo) 7.3 17 12.4 5.5 
a)This study just described the percentage of patients exposed to immunomodulatory drugs. b)The ORR of the study included the response rates 
of different regimens. c)The hematologic toxicity was based on grade 3/4 anemia. d)The hematologic toxicity was based on grade 3/4 
neutropenia.
Abbreviations: G, grade; OS, overall survival; PR, partial response; SCT, stem cell transplantation.
However, the bendamustine dosage may also have con-
tributed, since our patients received 120 mg/m2 of bendamus-
tine in combination with prednisolone. Accordingly, dosage 
modifications as well as active prophylaxis against infections 
should be considered when bendamustine is used in heavily 
pre-treated frail patients with MM. At the time of the final 
survival status update, only six patients were alive and the 
median OS after bendamustine treatment was 5.5 months. 
However, patients who responded to bendamustine showed 
a significant survival benefit compared with patients who 
did not (Fig. 2). Furthermore, 14 patients (22%) had survived 
＞12 months since they started bendamustine treatment 
(range, 12–45 mo), including the six patients who were still 
alive at the final follow-up. Some of the patients could be 
rescued by additional salvage treatments; this indicated that 
the extended OS after bendamustine was possible even after 
relapse or progression. Accordingly, bendamustine treatment 
could be used as a bridge treatment until newer treatments 
become available. The association of performance status and 
age at the time of bendamustine treatment with better OS 
also suggests that bendamustine treatment should be consid-
ered for salvage treatment in heavily pre-treated patients 
with MM, especially in patients≤60 years old, who have 
a good performance status. 
In conclusion, bendamustine may be effective in a select 
group of patients with relapsed or refractory MM. It repre-
sents a potential bridge treatment for heavily pre-treated 
patients, and may extend survival until newer treatment 
options become available. To our knowledge, this is the 
first report of the efficacy of bendamustine in Asian patients 
with MM. Further prospective studies are needed to confirm 
the efficacy of bendamustine-based treatments in Asian pa-
tients with MM. 
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